TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Naturopathic Treatment for the Prevention of Cardiovascular Disease: a Pragmatic Randomized Controlled Trial
Brief Summary: This study is designed to test the ability of a comprehensive naturopathic approach to reduce important risk factors for the development of cardiovascular disease. Treatment will take place over the course of one year and the comparator/control group will be followed by their medical doctors and be given conventional care.


Options:
A: Arm Label: High intensity intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Arm Label: Low intensity intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): High intensity intervention group, Low intensity intervention group
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Screening for hypertension, lower limb atherosclerosis and abdominal aortic aneurysm | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Screening for hypertension, lower limb atherosclerosis and abdominal aortic aneurysm; Assigned to Arm(s): 1
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Naturopathic medicine. May include: fish oil, plant sterols, soluble fiber, cinnamon, coQ10 and exercise | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional medical treatment (Atorvastatin,Fluvastatin,Lovastatin,Pravastatin,Rosuvastatin,Simvastatin) | Intervention Type: OTHER; Name: Naturopathic medicine. May include: fish oil, plant sterols, soluble fiber, cinnamon, coQ10 and exercise; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Conventional medical treatment (Atorvastatin,Fluvastatin,Lovastatin,Pravastatin,Rosuvastatin,Simvastatin); Assigned to Arm(s): 2
D: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Life style Intervention and care coordination; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated cardiovascular disease risk management. | Intervention Type: BEHAVIORAL; Name: Integrated cardiovascular disease risk management.; Assigned to Arm(s): Life style Intervention and care coordination

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effective Treatment for Prescription Opioid Abuse
Brief Summary: There has been an alarming increase in abuse of prescription opioids in recent years. This project aims to develop an effective outpatient treatment for prescription opioid (PO) abuse that combines an intensive behavioral therapy with a pharmacotherapy regimen of buprenorphine detoxification and naltrexone maintenance.


Options:
A: Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): N/A
B: Arm Label: 1-week buprenorphine taper; Type: EXPERIMENTAL; Interventions: Drug: buprenorphine taper followed by naltrexone maintenance, Behavioral: Behavioral therapy | Arm Label: 2-week buprenorphine taper; Type: EXPERIMENTAL; Interventions: Drug: buprenorphine taper followed by naltrexone maintenance, Behavioral: Behavioral therapy | Arm Label: 4-week buprenorphine taper; Type: EXPERIMENTAL; Interventions: Drug: buprenorphine taper followed by naltrexone maintenance, Behavioral: Behavioral therapy | Intervention Type: DRUG; Name: buprenorphine taper followed by naltrexone maintenance; Assigned to Arm(s): 1-week buprenorphine taper, 2-week buprenorphine taper, 4-week buprenorphine taper | Intervention Type: BEHAVIORAL; Name: Behavioral therapy; Assigned to Arm(s): 1-week buprenorphine taper, 2-week buprenorphine taper, 4-week buprenorphine taper
C: Intervention Type: DRUG; Name: buprenorphine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: naltrexone; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: behavior therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: voucher-based contingency management; Assigned to Arm(s): N/A
D: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effective Treatment for Prescription Opioid Abuse
Brief Summary: There has been an alarming increase in abuse of prescription opioids in recent years. This project aims to develop an effective outpatient treatment for prescription opioid (PO) abuse that combines an intensive behavioral therapy with a pharmacotherapy regimen of buprenorphine detoxification and naltrexone maintenance.


Options:
A: Arm Label: Buprenorphine/Nx with EMM; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Medical Management (EMM) of Prescription Opiate Abuse | Arm Label: Buprenorphine/Nx with SMM; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Medical Management (SMM) of Prescription Opiate Abuse | Intervention Type: BEHAVIORAL; Name: Standard Medical Management (SMM) of Prescription Opiate Abuse; Assigned to Arm(s): Buprenorphine/Nx with SMM | Intervention Type: BEHAVIORAL; Name: Enhanced Medical Management (EMM) of Prescription Opiate Abuse; Assigned to Arm(s): Buprenorphine/Nx with EMM
B: Arm Label: 1-week buprenorphine taper; Type: EXPERIMENTAL; Interventions: Drug: buprenorphine taper followed by naltrexone maintenance, Behavioral: Behavioral therapy | Arm Label: 2-week buprenorphine taper; Type: EXPERIMENTAL; Interventions: Drug: buprenorphine taper followed by naltrexone maintenance, Behavioral: Behavioral therapy | Arm Label: 4-week buprenorphine taper; Type: EXPERIMENTAL; Interventions: Drug: buprenorphine taper followed by naltrexone maintenance, Behavioral: Behavioral therapy | Intervention Type: DRUG; Name: buprenorphine taper followed by naltrexone maintenance; Assigned to Arm(s): 1-week buprenorphine taper, 2-week buprenorphine taper, 4-week buprenorphine taper | Intervention Type: BEHAVIORAL; Name: Behavioral therapy; Assigned to Arm(s): 1-week buprenorphine taper, 2-week buprenorphine taper, 4-week buprenorphine taper
C: Intervention Type: DRUG; Name: buprenorphine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: naltrexone; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: behavior therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: voucher-based contingency management; Assigned to Arm(s): N/A
D: Arm Label: Active electroacupuncture; Type: ACTIVE_COMPARATOR; Interventions: Device: Electroacupuncture | Arm Label: Sham electroacupuncture; Type: SHAM_COMPARATOR; Interventions: Device: Electroacupuncture | Intervention Type: DEVICE; Name: Electroacupuncture; Assigned to Arm(s): Active electroacupuncture, Sham electroacupuncture

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating the Effect of Aprepitant on Cyclophosphamide Pharmacokinetics
Brief Summary: RATIONALE: Antiemetic drugs, such as aprepitant, may help lessen or prevent nausea and vomiting in patients undergoing chemotherapy.

PURPOSE: This randomized clinical trial is studying aprepitant to see how well it works compared to placebo in preventing nausea and vomiting in patients undergoing chemotherapy for breast cancer.


Options:
A: Arm Label: Placebo + Granisetron + Dexamethasone; Type: PLACEBO_COMPARATOR; Interventions: Drug: Granisetron, Drug: Dexamethasone, Drug: Placebo | Arm Label: Rolapitant; Type: EXPERIMENTAL; Interventions: Drug: Rolapitant, Drug: Granisetron, Drug: Dexamethasone | Intervention Type: DRUG; Name: Rolapitant; Assigned to Arm(s): Rolapitant | Intervention Type: DRUG; Name: Granisetron; Assigned to Arm(s): Placebo + Granisetron + Dexamethasone, Rolapitant | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Placebo + Granisetron + Dexamethasone, Rolapitant | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Granisetron + Dexamethasone
B: Arm Label: Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel | Arm Label: Docetaxel/Casopitant; Type: EXPERIMENTAL; Interventions: Drug: Casopitant/Docetaxel | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Docetaxel | Intervention Type: DRUG; Name: Casopitant/Docetaxel; Assigned to Arm(s): Docetaxel/Casopitant
C: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: aprepitant, Drug: cyclophosphamide, Other: placebo | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: aprepitant, Drug: cyclophosphamide, Other: placebo | Intervention Type: DRUG; Name: aprepitant; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Arm I, Arm II | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm I, Arm II
D: Arm Label: Standard PO (Zofran + Dexamethasone); Type: PLACEBO_COMPARATOR; Interventions: Drug: Standard PO (Zofran + Dexamethason) | Arm Label: Aprepitant (MK-869) + Standard PO; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aprepitant (MK-869) + Standard PO | Intervention Type: DRUG; Name: Standard PO (Zofran + Dexamethason); Assigned to Arm(s): Standard PO (Zofran + Dexamethasone) | Intervention Type: DRUG; Name: Aprepitant (MK-869) + Standard PO; Assigned to Arm(s): Aprepitant (MK-869) + Standard PO

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label, Multi-center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2a Plus Bevacizumab for the First-line Treatment of Patients With Metastatic Clear Cell Carcinoma of the Kidney
Brief Summary: To estimate the difference in efficacy and safety of bevacizumab and RAD001 compared to bevacizumab and interferon alfa-2a for first-line treatment of patients with metastatic carcinoma of the kidney.


Options:
A: Arm Label: Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm B: Sunitinib 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Nivolumab, Biological: Ipilimumab, Drug: Sunitinib | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg, Arm B: Sunitinib 50 mg | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg, Arm B: Sunitinib 50 mg | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Arm B: Sunitinib 50 mg
B: Arm Label: Sorafenib Tosylate; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib Tosylate, Other: Laboratory Biomarker Analysis | Arm Label: Sorafenib Tosylate, Recombinant interferon alfa-2b; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib Tosylate, Biological: Recombinant Interferon Alfa-2b, Other: Laboratory Biomarker Analysis | Intervention Type: DRUG; Name: Sorafenib Tosylate; Assigned to Arm(s): Sorafenib Tosylate, Sorafenib Tosylate, Recombinant interferon alfa-2b | Intervention Type: BIOLOGICAL; Name: Recombinant Interferon Alfa-2b; Assigned to Arm(s): Sorafenib Tosylate, Recombinant interferon alfa-2b | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Sorafenib Tosylate, Sorafenib Tosylate, Recombinant interferon alfa-2b
C: Arm Label: bevacizumab, RAD001 (everolimus); Type: EXPERIMENTAL; Interventions: Drug: RAD001(everolimus), Drug: bevacizumab | Arm Label: bevacizumab, interferon alfa-2a (IFN); Type: ACTIVE_COMPARATOR; Interventions: Drug: interferon alfa-2a, Drug: bevacizumab | Intervention Type: DRUG; Name: RAD001(everolimus); Assigned to Arm(s): bevacizumab, RAD001 (everolimus) | Intervention Type: DRUG; Name: interferon alfa-2a; Assigned to Arm(s): bevacizumab, interferon alfa-2a (IFN) | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): bevacizumab, RAD001 (everolimus), bevacizumab, interferon alfa-2a (IFN)
D: Intervention Type: DRUG; Name: Avastin (bevacizumab); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Tarceva (erlotinib HCl); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label, Multi-center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2a Plus Bevacizumab for the First-line Treatment of Patients With Metastatic Clear Cell Carcinoma of the Kidney
Brief Summary: To estimate the difference in efficacy and safety of bevacizumab and RAD001 compared to bevacizumab and interferon alfa-2a for first-line treatment of patients with metastatic carcinoma of the kidney.


Options:
A: Arm Label: bevacizumab, RAD001 (everolimus); Type: EXPERIMENTAL; Interventions: Drug: RAD001(everolimus), Drug: bevacizumab | Arm Label: bevacizumab, interferon alfa-2a (IFN); Type: ACTIVE_COMPARATOR; Interventions: Drug: interferon alfa-2a, Drug: bevacizumab | Intervention Type: DRUG; Name: RAD001(everolimus); Assigned to Arm(s): bevacizumab, RAD001 (everolimus) | Intervention Type: DRUG; Name: interferon alfa-2a; Assigned to Arm(s): bevacizumab, interferon alfa-2a (IFN) | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): bevacizumab, RAD001 (everolimus), bevacizumab, interferon alfa-2a (IFN)
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1
C: Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: IMA901 plus GM-CSF added to sunitinib after single dose of cy; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib, Biological: GM-CSF, Drug: Cyclophosphamide, Drug: IMA901 | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy, Sunitinib | Intervention Type: BIOLOGICAL; Name: GM-CSF; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy | Intervention Type: DRUG; Name: IMA901; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy
D: Arm Label: A-immunotherapy; Type: EXPERIMENTAL; Interventions: Drug: Interferon Alfa-2a, Drug: Interleukin-2 | Arm Label: B-follow-up; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Interferon Alfa-2a; Assigned to Arm(s): A-immunotherapy | Intervention Type: DRUG; Name: Interleukin-2; Assigned to Arm(s): A-immunotherapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label, Multi-center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2a Plus Bevacizumab for the First-line Treatment of Patients With Metastatic Clear Cell Carcinoma of the Kidney
Brief Summary: To estimate the difference in efficacy and safety of bevacizumab and RAD001 compared to bevacizumab and interferon alfa-2a for first-line treatment of patients with metastatic carcinoma of the kidney.


Options:
A: Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: Pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: temsirolimus (Torisel) | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: temsirolimus (Torisel); Assigned to Arm(s): 2
C: Arm Label: Alternating regimen; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Drug: Everolimus | Arm Label: Sequential treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pazopanib, Drug: Everolimus | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Sequential treatment | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Sequential treatment | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Alternating regimen | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Alternating regimen | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Alternating regimen | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Alternating regimen
D: Arm Label: bevacizumab, RAD001 (everolimus); Type: EXPERIMENTAL; Interventions: Drug: RAD001(everolimus), Drug: bevacizumab | Arm Label: bevacizumab, interferon alfa-2a (IFN); Type: ACTIVE_COMPARATOR; Interventions: Drug: interferon alfa-2a, Drug: bevacizumab | Intervention Type: DRUG; Name: RAD001(everolimus); Assigned to Arm(s): bevacizumab, RAD001 (everolimus) | Intervention Type: DRUG; Name: interferon alfa-2a; Assigned to Arm(s): bevacizumab, interferon alfa-2a (IFN) | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): bevacizumab, RAD001 (everolimus), bevacizumab, interferon alfa-2a (IFN)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Neonatal Erythropoietin in Asphyxiated Term Newborns: a Phase I Trial
Brief Summary: The purpose of this study is to determine the safety and pharmacokinetics of moderate to high doses of erythropoietin in newborn infants with birth asphyxia.


Options:
A: Arm Label: PNEUMOSTEM®; Type: EXPERIMENTAL; Interventions: Biological: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells | Intervention Type: BIOLOGICAL; Name: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells; Assigned to Arm(s): PNEUMOSTEM®
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: erythropoietin | Intervention Type: DRUG; Name: erythropoietin; Assigned to Arm(s): A
C: Arm Label: infusions; Type: EXPERIMENTAL; Interventions: Biological: infusion of autologous cord blood | Arm Label: historical control; Type: OTHER; Interventions: Other: Neurodevelopmental outcomes | Intervention Type: BIOLOGICAL; Name: infusion of autologous cord blood; Assigned to Arm(s): infusions | Intervention Type: OTHER; Name: Neurodevelopmental outcomes; Assigned to Arm(s): historical control
D: Arm Label: Autologous hMSCs; Type: ACTIVE_COMPARATOR; Interventions: Biological: Autologous hMSCs | Arm Label: Allogeneic hMSCs; Type: ACTIVE_COMPARATOR; Interventions: Biological: Allogeneic hMSCs | Intervention Type: BIOLOGICAL; Name: Autologous hMSCs; Assigned to Arm(s): Autologous hMSCs | Intervention Type: BIOLOGICAL; Name: Allogeneic hMSCs; Assigned to Arm(s): Allogeneic hMSCs

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Functional Recovery in Stroke Patients With Task-Specific Robot-Aided Arm Therapy
Brief Summary: The goal of this study is to determine whether task-oriented, robot-aided therapy is more effective than conventional physical and occupational therapy at promoting functional recovery of the affected arm in chronic hemiparetic stroke patients.


Options:
A: Arm Label: Hand Mentor Therapy; Type: EXPERIMENTAL; Interventions: Device: Hand Mentor (TM) robotic stroke therapy device | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: Home Therapy Program | Intervention Type: DEVICE; Name: Hand Mentor (TM) robotic stroke therapy device; Assigned to Arm(s): Hand Mentor Therapy | Intervention Type: DEVICE; Name: Home Therapy Program; Assigned to Arm(s): Control
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: robot therapy (ARMin) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: conventional therapy | Intervention Type: DEVICE; Name: robot therapy (ARMin); Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: conventional therapy; Assigned to Arm(s): 2
C: Arm Label: ArmAssist therapy; Type: EXPERIMENTAL; Interventions: Device: ArmAssist robotic training, Other: Conventional therapy | Arm Label: Conventional therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional therapy | Arm Label: Extended Conventional therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional therapy, Other: Extended conventional therapy | Intervention Type: DEVICE; Name: ArmAssist robotic training; Assigned to Arm(s): ArmAssist therapy | Intervention Type: OTHER; Name: Conventional therapy; Assigned to Arm(s): ArmAssist therapy, Conventional therapy, Extended Conventional therapy | Intervention Type: OTHER; Name: Extended conventional therapy; Assigned to Arm(s): Extended Conventional therapy
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Device: Robot-Assisted Therapy - MIT-MANUS System | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Intensive Comparison Therapy | Arm Label: Arm 3; Type: OTHER; Interventions: Other: Usual Care | Intervention Type: DEVICE; Name: Robot-Assisted Therapy - MIT-MANUS System; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: Intensive Comparison Therapy; Assigned to Arm(s): Arm 2 | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Arm 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Functional Recovery in Stroke Patients With Task-Specific Robot-Aided Arm Therapy
Brief Summary: The goal of this study is to determine whether task-oriented, robot-aided therapy is more effective than conventional physical and occupational therapy at promoting functional recovery of the affected arm in chronic hemiparetic stroke patients.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: robot therapy (ARMin) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: conventional therapy | Intervention Type: DEVICE; Name: robot therapy (ARMin); Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: conventional therapy; Assigned to Arm(s): 2
B: Arm Label: Experimental Group (EG); Type: EXPERIMENTAL; Interventions: Device: Robot therapy (NeReBot), Other: Conventional therapy | Arm Label: Control Group (CG); Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional therapy | Intervention Type: DEVICE; Name: Robot therapy (NeReBot); Assigned to Arm(s): Experimental Group (EG) | Intervention Type: OTHER; Name: Conventional therapy; Assigned to Arm(s): Control Group (CG), Experimental Group (EG)
C: Arm Label: E-glove system; Type: EXPERIMENTAL; Interventions: Device: E-glove system | Arm Label: Conventional occupational therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional occupational therapy | Intervention Type: DEVICE; Name: E-glove system; Assigned to Arm(s): E-glove system | Intervention Type: PROCEDURE; Name: Conventional occupational therapy; Assigned to Arm(s): Conventional occupational therapy
D: Arm Label: Hand Mentor Therapy; Type: EXPERIMENTAL; Interventions: Device: Hand Mentor (TM) robotic stroke therapy device | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: Home Therapy Program | Intervention Type: DEVICE; Name: Hand Mentor (TM) robotic stroke therapy device; Assigned to Arm(s): Hand Mentor Therapy | Intervention Type: DEVICE; Name: Home Therapy Program; Assigned to Arm(s): Control

Answer: A